Neurology perspectives最新文献

{"title":"Multiple sclerosis and rheumatic diseases: Behçet disease, sarcoidosis, and Sjögren syndrome","authors":"M.A. Hernández ,&nbsp;Y. Contreras ,&nbsp;B. González ,&nbsp;L.M. Armas","doi":"10.1016/j.neurop.2025.100198","DOIUrl":"10.1016/j.neurop.2025.100198","url":null,"abstract":"<div><h3>Introduction</h3><div>Multiple sclerosis can be associated with a range of rheumatic processes. Behçet disease is a relapsing, multisystemic, immune-mediated chronic vasculitic disorder of unknown aetiology, whose symptoms overlap with those of many autoinflammatory processes. Sarcoidosis is a universally distributed multisystem granulomatous disease. Sjögren syndrome is a chronic, autoimmune, inflammatory disease characterised by lymphocytic infiltration in exocrine glands, which causes xerostomia (dry mouth) and xerophthalmia (dry eyes). The most frequent extraglandular manifestations of the syndrome are musculoskeletal problems.</div></div><div><h3>Development</h3><div>We describe the most significant neurological complications of these rheumatic diseases, as well as the pharmacological treatments that may be indicated for these conditions and the possible contraindications in patients receiving treatment for multiple sclerosis.</div></div><div><h3>Conclusions</h3><div>We provide a series of recommendations for the treatment of patients with multiple sclerosis who also present with Behçet disease, sarcoidosis, or Sjögren syndrome. Co-presence of any of these rheumatic diseases constitutes a contraindication for some treatments.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 3","pages":"Article 100198"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144557469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoimmune eye diseases in multiple sclerosis","authors":"M.L. Martínez Ginés ,&nbsp;P. Rojas Lozano","doi":"10.1016/j.neurop.2025.100195","DOIUrl":"10.1016/j.neurop.2025.100195","url":null,"abstract":"<div><h3>Introduction</h3><div>The eye is a complex organ that can present complications related to autoimmune diseases, including multiple sclerosis (MS). Ocular manifestations may act as early indicators of autoimmune diseases, and their early diagnosis and treatment are essential to guaranteeing patients' quality of life. This review analyses the main autoimmune eye diseases associated with MS, focusing on intermediate uveitis and its personalised management.</div></div><div><h3>Development</h3><div>MS-associated uveitis includes various forms of intraocular inflammation affecting different areas of the eye. The relationship between MS and uveitis is complex and involves shared immunological mechanisms and diagnostic and therapeutic challenges. The clinical presentation of uveitis varies from asymptomatic forms to severe vision-threatening complications. The treatment of uveitis involves careful assessment and the consideration of immunomodulatory or immunosuppressive treatment with a view to controlling inflammation and preventing visual sequelae.</div></div><div><h3>Conclusions</h3><div>Treatment of MS-related uveitis is complex and requires a multidisciplinary approach. Advances in immunomodulatory therapy offer new treatment options, as well as challenges related to adverse reactions and disease management. Further research is needed to better understand the relationship between MS and eye diseases, and to optimise therapeutic strategies and improve patients' visual and neurological outcomes.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 3","pages":"Article 100195"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144536222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of the most prevalent autoimmune diseases co-occurring with Multiple Sclerosi","authors":"A.B. Caminero","doi":"10.1016/j.neurop.2025.100194","DOIUrl":"10.1016/j.neurop.2025.100194","url":null,"abstract":"","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 3","pages":"Article 100194"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144557116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoimmune skin diseases in multiple sclerosis","authors":"M. Roncero Riesco ,&nbsp;A. Cabanillas Cabral ,&nbsp;Y. El Berdei Montero","doi":"10.1016/j.neurop.2025.100200","DOIUrl":"10.1016/j.neurop.2025.100200","url":null,"abstract":"<div><h3>Introduction</h3><div>Autoimmune dermatological diseases have a prevalence greater than 2% in the general population, sometimes as a primary disorder and other times within a context of systemic involvement. Comorbidity with multiple sclerosis (MS) has been described, particularly in the case of psoriasis and bullous pemphigoid, and to a lesser extent in pemphigus vulgaris and other autoimmune skin diseases.</div></div><div><h3>Development</h3><div>Psoriasis is the autoimmune skin disease for which the most evidence is available on this association, with increased risk in patients with MS. Both disorders probably have common pathophysiological mechanisms. The joint treatment of both diseases will depend on the degree of activity of each one, but in general, it is recommended for patients with MS and psoriasis to avoid interferons, teriflunomide, and anti-CD20 monoclonal antibodies, whereas fumarates and S1P receptor antagonists are recommended. TNF-α inhibitors are formally contraindicated in MS. In the case of bullous pemphigoid, pemphigus vulgaris, and other less common autoimmune dermatological diseases, the relationship with MS is not so clearly established, although an association between the first 2 and neurological diseases, including MS, has been described. Treatment is based on corticotherapy, and classic immunosuppressants or rituximab may be combined, which represent an alternative for joint treatment.</div></div><div><h3>Conclusions</h3><div>Comorbidity between MS and autoimmune dermatological disorders, and especially psoriasis, requires a joint approach, avoiding treatments that may aggravate one or the other disorders.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 3","pages":"Article 100200"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144535783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Findings in orofacial praxis in clinical swallow examination in patients with neurogenic oropharyngeal dysphagia","authors":"J.C. Suárez-Escudero ,&nbsp;V. De Alba-Higuita ,&nbsp;J. Bareño-Silva","doi":"10.1016/j.neurop.2025.100191","DOIUrl":"10.1016/j.neurop.2025.100191","url":null,"abstract":"<div><h3>Introduction</h3><div>Praxis facilitate the execution of learned motor acts, including swallowing. Inability to perform praxis movements, or apraxia, may be classified according to different criteria. Buccopharyngeal apraxia includes orofacial apraxia. Clinical swallow evaluation does not typically include assessment of oropharyngeal/orofacial praxes; however, this would be of great semiological value, particularly in patients with neurological and neuromuscular disorders who present with dysphagia. The objective of this study was to explore and compare findings from the assessment of 3 orofacial praxis in healthy individuals without dysphagia and in patients with neurogenic oropharyngeal dysphagia, as part of the clinical swallow examination.</div></div><div><h3>Methods</h3><div>We designed a case–control study based on a clinical swallow examination that included an assessment of 3 orofacial praxis. Comparisons were made, and odds ratios with 95% confidence intervals were calculated. Non-performance of the 3 orofacial praxis was recorded separately and jointly, adjusting for sex and age in both groups, as well as for other clinical variables of interest in the patient group.</div></div><div><h3>Results</h3><div>Our study included 86 patients and 80 controls. Oral motor apraxia was associated with oropharyngeal dysphagia; more specifically, the presence of neurogenic oropharyngeal dysphagia was found to be associated with difficulty in moving both lips together to either side, as well as with such other physical examination findings as tongue fasciculations and atrophy, and impaired tongue coordination. No statistically significant association was observed with age or sex in either group.</div></div><div><h3>Conclusion</h3><div>Assessment of orofacial praxes can help to identify patients with neurogenic oropharyngeal dysphagia.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 3","pages":"Article 100191"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143821422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of COVID-19 on physiotherapy for patients with multiple sclerosis in Spain: Adaptation and challenges in the implementation of telerehabilitation","authors":"I. Yeregui-Prieto ,&nbsp;R. Berriozabalgoitia Etxaniz ,&nbsp;N. Martínez Lerín ,&nbsp;G. Yaya-Tur ,&nbsp;G. Loyola ,&nbsp;E.R. Meza-Murillo ,&nbsp;C. Santoyo-Medina","doi":"10.1016/j.neurop.2025.100188","DOIUrl":"10.1016/j.neurop.2025.100188","url":null,"abstract":"<div><h3>Introduction</h3><div>The COVID-19 pandemic, declared in March 2020, had a profound impact on health services in Spain, especially on physiotherapy for people with multiple sclerosis (PwMS). The health reorganization forced the suspension of rehabilitation services, affecting millions of people with disabilities in Europe.</div></div><div><h3>Objective</h3><div>To evaluate the impact of the pandemic on the clinical practice of the Physiotherapy Collective (CF) specialized in multiple sclerosis (MS) in Spain, highlighting the changes in interventions and the use of telerehabilitation (TRHB).</div></div><div><h3>Materials and methods</h3><div>An international survey was designed and disseminated in Spain through MS associations. The sample included 32 physiotherapists. The statistical analysis was performed with IBM SPSS, with a significance level of <em>p</em> ≤ 0.05.</div></div><div><h3>Results</h3><div>A total of 78% of physiotherapists worked with PwMS before the pandemic, and the use of TRHB increased to 29.24%. A reduction in face-to-face interventions, especially in manual therapies, was observed, mainly affecting patients with severely impaired mobility (SIM). However, 81.3% kept aerobic training sessions online. The main barriers were the lack of devices and the difficulty in conducting adequate assessments.</div></div><div><h3>Conclusions</h3><div>The pandemic not only underscored the importance of TRHB but also exposed key limitations. Future research should focus on improving its feasibility and providing appropriate training to optimize care for PwMS.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 2","pages":"Article 100188"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paroxysmal tonic upgaze with epileptiform discharges and calcarine sulcus lesion","authors":"Nazaret Peláez Viña ,&nbsp;Dennis Dunlop Bórquez ,&nbsp;Eva Negro Moral ,&nbsp;Maite Cáceres","doi":"10.1016/j.neurop.2025.100185","DOIUrl":"10.1016/j.neurop.2025.100185","url":null,"abstract":"","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 2","pages":"Article 100185"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143737910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guillain-Barré syndrome following acute hepatitis E virus infection: A novel Indian case report with acute inflammatory demyelinating polyneuropathy pattern and anti-GM1 antibodies","authors":"R. Ghosh ,&nbsp;M. León-Ruiz ,&nbsp;A.S. Mondal ,&nbsp;S. Dubey ,&nbsp;J. Benito-León","doi":"10.1016/j.neurop.2025.100187","DOIUrl":"10.1016/j.neurop.2025.100187","url":null,"abstract":"","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 2","pages":"Article 100187"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143682517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and immune evolution in neurological/psychiatric patients during the COVID-19 pandemic","authors":"A. Toledo ,&nbsp;M.A. Gaona ,&nbsp;T. Delgadillo ,&nbsp;C.T. Arellano ,&nbsp;A. Padilla ,&nbsp;S. Bravo ,&nbsp;H. Alipi ,&nbsp;V. Toledo ,&nbsp;M.A. Del Rio Quiñones ,&nbsp;D.L. De la Cruz-Aguilera ,&nbsp;L. Aguirre-Cruz ,&nbsp;A. Fleury","doi":"10.1016/j.neurop.2025.100189","DOIUrl":"10.1016/j.neurop.2025.100189","url":null,"abstract":"<div><h3>Introduction</h3><div>The COVID-19 pandemic has had a disastrous impact on the world's population. Its effects were mainly respiratory, but resulting neurological damage has also been described. In this context, we evaluated the effects of COVID-19 on the subjective perception of neurological and psychiatric symptoms in patients with pre-pandemic neuropsychiatric diseases, as well as the possible association between the evolution of these symptoms and immunological factors.</div></div><div><h3>Methods</h3><div>A cohort of neurological/psychiatric patients with (n = 99) or without (n = 42) a history of COVID-19 was included. Inclusion took place 7 months after COVID-19 infection, and follow-up was performed 14 months after inclusion. At both assessments, included subjects were asked whether they considered their neurological/psychiatric symptoms to be stable, worsened or improved compared with the situation before COVID-19, or compared with the first assessment. A blood sample of all subjects was taken at both assessments to determine levels of several cytokines<strong>.</strong></div></div><div><h3>Results</h3><div>A worsening of neurological/psychiatric symptoms was reported by 36.9% of patients, when comparing the situation at follow-up with that prior to COVID-19. Comparing with controls, patients with history of COVID-19 had significantly higher levels of IL-6 and IFN-γ, and patients with a history of symptomatic COVID-19 presented a significant higher level of IL-10. IFN-γ was significantly associated with COVID-19 severity, and its decrease during follow-up was associated with improvement of neurological/psychiatric symptoms in neurological patients with a history of COVID-19, but not in control patients.</div></div><div><h3>Conclusions</h3><div>More than 35% of included neuropsychiatric patients have reported worsening of symptoms after non-severe COVID-19. IFN-γ seems to be a marker linked to COVID-19 pathogeny and its evaluation might be useful for monitoring affected patients.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 2","pages":"Article 100189"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143682518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stroke machine learning for discharge planning: A pilot implementation study","authors":"S. Bacchi ,&nbsp;R. Goh ,&nbsp;J. Kovoor ,&nbsp;S. Gluck ,&nbsp;L. Oakden-Rayner ,&nbsp;S. Koblar ,&nbsp;T. Kleinig ,&nbsp;J. Jannes","doi":"10.1016/j.neurop.2025.100183","DOIUrl":"10.1016/j.neurop.2025.100183","url":null,"abstract":"","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 2","pages":"Article 100183"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143535201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}